1xbet.com Bristol-Myers K.K.
1xbet.com

Bristol-Myers Squibb and 1xbet.com announced the results of Japanese subset analysis in a Phase III DASISION study on the efficacy of SPRYCEL compared with imatinib for the treatment of patients with newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP). In this analysis, the primary endpoint was the confirmed Complete Cytogenetic Response (CCyR^*) rate by 12 months. In 1xbet.com Japanese subset analysis, confirmed CCyR was 96% for 1xbet.com SPRYCEL group (26 cases) and 70% for 1xbet.com imatinib control group (23 cases), showing high efficacy of SPRYCEL in 1xbet.com Japanese subset. As for safety profiles, it was concluded that both groups showed good tolerability. 1xbet.com results of this analysis were presented at 1xbet.com 52^ndAnnual Meeting of 1xbet.com American Society of Hematology, held in Orlando, Florida.

• *Complete cytogenetic response (CCyR) is defined as 1xbet.com state where bone marrow cell genetic evaluation finds no Philadelphia chromosome positive cells undergoing mitosis.